What to eat on retatrutide: there is no approved diet plan.
Retatrutide is an investigational triple agonist with five positive phase 3 studies reported by Eli Lilly, but as of 20 October 2026 it has not been approved by the TGA or any comparable regulator, and Lilly plans its first US application in early 2027. It is not a medicine people can lawfully buy from peptide websites, and no evidence-based public retatrutide meal plan has been established.
Do not take a product claiming to be retatrutide outside an authorised clinical trial.
Eli Lilly states that retatrutide has not been approved by any regulatory agency and warns that illicit products may contain unknown ingredients, contaminants, too much or too little active ingredient, or the wrong ingredient. The TGA also identifies retatrutide as an unapproved therapeutic good that cannot be advertised to the public.
A triple agonist, not “GLP-3”.
Retatrutide is being studied for effects at three receptors: GIP, GLP-1 and glucagon. “GLP-3” is an informal and scientifically inaccurate nickname; it is not a drug class or receptor.
The correct spelling is retatrutide. Search variations such as “retratutide” usually intend the same investigational compound. A search result does not establish that a product is genuine, approved or safe.
Trials included diet and activity.
Phase 3 programs studied retatrutide under controlled protocols, commonly alongside healthy diet and physical activity. That does not create a public treatment or meal plan.
No approved nutrition protocol.
There is no regulator-approved retatrutide Consumer Medicine Information, dose schedule or standard food list for public use.
Online “research” products.
Products sold online as retatrutide sit outside the safeguards of an authorised clinical trial and may be counterfeit or contaminated.
A “retatrutide meal plan” page can imply a treatment exists when it does not.
Some pages publish precise calorie plans, dosing-adjacent advice or claims about preventing side effects. Those claims should not be treated as established clinical guidance. Trial results answer research questions in selected participants; they do not validate a commercial diet plan for an unapproved medicine.
People seeking general information about eating with an approved GLP-1 or dual GIP/GLP-1 medicine should use the current Australian Product Information for that medicine and ask their own clinician or Accredited Practising Dietitian. Our general GLP-1 food guide discusses nutrition concepts without claiming they apply to investigational retatrutide.
For a fuller picture, see our retatrutide meals page (trial status, receptor science and the high-protein meals that suit a reduced appetite today) and the retatrutide meal plan explainer (why no approved plan exists and the general framework people use to plan ahead).
What has happened to people using unapproved “retatrutide” in Australia?
- Liver injury in Victoria. On 19 June 2026 Victoria's Chief Health Officer reported six cases of acute liver injury since January 2026 in people who used unapproved products labelled Retatrutide (also sold as “Reta”, “R-10” and “R-20”). Source: Victorian Department of Health alert, 19 June 2026.
- A counterfeit vial. After a person needed hospital care for uncontrollable vomiting and a torn oesophagus, TGA testing found no retatrutide in the product, only undeclared semaglutide at about eight times the level in registered products. Source: TGA safety alert, 14 September 2026.
- Seizures. The TGA and NSW Police seized more than $120,000 of peptide and steroid products, including retatrutide, in August 2026. Source: TGA, 17 August 2026.
If you have used one of these products and feel unwell, see a doctor, call the Poisons Information Centre on 13 11 26, or call 000 in an emergency. Trial results and side effects are covered in retatrutide in Australia and retatrutide side effects.
Is there a retatrutide diet plan?
No. Retatrutide is not approved by the TGA or any comparable regulator as of 20 October 2026, so there is no Consumer Medicine Information, approved dose schedule or official food plan for public use. Trial participants followed research protocols that included diet and activity advice.
What should I eat if I am in a retatrutide trial?
Follow the trial team's instructions. Clinical trials have their own safety monitoring and nutrition advice, and changes to how you eat should be discussed with the investigators rather than taken from a website.
Is retatrutide approved in Australia?
No. The TGA stated on 14 September 2026 that retatrutide has not been approved by the TGA or any comparable international regulator. Eli Lilly says it is legally available only to participants in its clinical trials.
Is it legal to buy retatrutide online in Australia?
The TGA says it is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia, and that any retatrutide accessed outside clinical trials could be counterfeit. Products sold as research peptides are not a safe or lawful route to the medicine.
What is a reta diet?
“Reta” is street shorthand for products sold as retatrutide. A “reta diet” is not an established plan. The general eating patterns used with approved GLP-1 medicines (smaller meals, protein first, fluids, fibre as tolerated) are described in our GLP-1 meal plan, which is not specific to retatrutide.
Retatrutide explainers: Retatrutide in Australia · Retatrutide side effects · Retatrutide vs tirzepatide
Important: This is a regulatory and food-information explainer, not medical advice or promotion. Preptide does not supply, recommend or facilitate access to retatrutide or any prescription or investigational medicine. Regulatory status can change; check the TGA and the sponsor's official information. See our editorial policy.